IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: GlobeNewswire
AUSTIN, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. To begin the interview, Dr. Schaber addressed the upcoming interim analysis of the company’s Phase 3 FLASH2 study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (“CTCL”). “Well, fi
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 [Yahoo! Finance]Yahoo! Finance
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026PR Newswire
- Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication [Yahoo! Finance]Yahoo! Finance
- Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"PR Newswire
- Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency [Yahoo! Finance]Yahoo! Finance
SNGX
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/12/26 - Form 8-K
- 1/23/26 - Form 424B5
- SNGX's page on the SEC website